Trastuzumab - Cancer Precision Medicine

Trastuzumab deruxtecan trastuzumab

Trastuzumab emtansine is a HER2-targeted, microtubule-stabilizing antibody-drug conjugate with about 3 chemotherapy molecules per antibody

trastuzumab trastuzumab Early breast cancer Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery For treating certain types of breast, stomach or esophagus cancers, and othersTrastuzumab is available as a biosimilar medication See our biosimilar pamphlet Comment: Trastuzumab is a humanized IgG1κ monoclonal antibody targeting HER2 Annotated peptide sequences for this antibody are available from its IMGTmAb-DB

เลียม เพย์น trastuzumab Early breast cancer Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery